Vaccines against influenza A (H5N1): Evidence of progress

Journal of Infectious Diseases

Volumn 198, Issue 5, 2008, Pages 629-631

  Poland, Gregory A ^a   Sambhara, Suryaprakash ^b  

^a Mayo Vaccine Research Group   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACULOVIRUS VECTOR; HEMAGGLUTININ; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE;

ANTIBODY TITER; CLINICAL TRIAL; DOSE RESPONSE; DRUG FORMULATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HEMAGGLUTINATION INHIBITION TEST; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; INJECTION SITE PAIN; MORBIDITY; MORTALITY; NOTE; PANDEMIC; PRIORITY JOURNAL; SERODIAGNOSIS; SEROLOGY; UNSPECIFIED SIDE EFFECT; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

CLINICAL TRIALS AS TOPIC; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 50949108220     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/590912     Document Type: Note

References (13)

1. World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. Available at: http://www.who.int/csr/ disease/avian_influenza/country/cases_table_2008_04_30/en/index.html. Accessed 16 May 2008.
2. Congressional Budget Office. A potential influenza pandemic: possible macroeconomic effects and policy issues. 8 December 2005. Available at: http://www.cbo.gov/ftpdocs/69xx/doc6946/12-08-BirdFlu.pdf. Accessed 19 June 2008.
3. Poland GA. Vaccines against avian influenza: a race against time. N Engl J Med 2006; 354:1411-3.
4. Goji NA, Nolan C, Hill H, et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 2008; 198:635-41 (in this issue).
5. Levie K, Leroux-Roels I, Hoppenbrouwers K, et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008; 198:642-9 (in this issue).
6. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9.
7. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937-43.
8. Stephenson I, Nicholson KG, Colegate A, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003; 21:1687-93.
9. Sedyaningsih ER, Isfandari S, Setiawaty V, et al. Epidemiology of cases of H5N1 virus infection in Indonesia, July 2005-June 2006. J Infect Dis 2007; 196:522-7.
10. Poland GA, Ovsyannikova IG, Jacobson RM, et al. Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine 2001; 20:430-8.
11. Ovsyannikova IG, Jacobson RM, Dhiman N, Vierkant RA, Pankratz VS, Poland GA. Human leukocyte antigen and cytokine receptor gene polymorphisms associated with heterogeneous immune responses to mumps viral vaccine. Pediatrics 2008; 121:e1091-9.
12. Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther 2007; 82:653-64.
13. Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 2004; 39:978-88.